Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 43537 | 3.64 |
09:34 ET | 11401 | 3.6349 |
09:36 ET | 5500 | 3.64 |
09:38 ET | 2529 | 3.6305 |
09:39 ET | 7879 | 3.625 |
09:41 ET | 128013 | 3.605 |
09:43 ET | 38661 | 3.6 |
09:45 ET | 41775 | 3.595 |
09:48 ET | 128714 | 3.615 |
09:50 ET | 85566 | 3.605 |
09:52 ET | 31339 | 3.5999 |
09:54 ET | 81073 | 3.605 |
09:56 ET | 17641 | 3.595 |
09:57 ET | 75641 | 3.605 |
09:59 ET | 53314 | 3.625 |
10:01 ET | 10556 | 3.625 |
10:03 ET | 20148 | 3.615 |
10:06 ET | 8570 | 3.63 |
10:08 ET | 16732 | 3.635 |
10:10 ET | 7600 | 3.635 |
10:12 ET | 10428 | 3.64 |
10:14 ET | 27551 | 3.665 |
10:15 ET | 2998 | 3.68 |
10:17 ET | 83329 | 3.645 |
10:19 ET | 85584 | 3.65 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.2B | -10.5x | --- |
Vera Therapeutics Inc | 2.1B | -18.5x | --- |
CG Oncology Inc | 2.1B | -27.7x | --- |
Rocket Pharmaceuticals Inc | 2.0B | -7.7x | --- |
Janux Therapeutics Inc | 2.4B | -37.1x | --- |
Keros Therapeutics Inc | 1.8B | -9.7x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.2B |
---|---|
Revenue (TTM) | $520.0K |
Shares Outstanding | 593.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.43 |
EPS | $-0.35 |
Book Value | $0.46 |
P/E Ratio | -10.5x |
Price/Sales (TTM) | 4,174.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -40,381.92% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.